Cumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update August 10, 2021 Year-to-date net revenues up 9.3% NASHVILLE, Tenn., Aug. 10, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial results. Net revenues from continuing operations during the quarter were $9.1 million and totaled $19.6 million for the first half of 2021. The company also recorded an a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 Cumberland Pharmaceuticals Inc. (Exact Name of Registrant as Specified In Its Charter) Tennessee 62-1765329 (State or Othe ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q2 2021 Results Earnings Conference Call August 10, 2021 4:30 PM ET Company Participants Molly Aggas - Senior Account Manager, Dalton Agency, IR A.J. Kazimi - Chairman and Chief Executive Officer Marty Cearnal - President and Chief Commercial Officer John Hamm - Chief Financial Officer Conference Call Participants Operator Thank you for joining the Cumberland Pharmaceuticals Second Quarter 2021 Financial Report and Company Update. This call is being recorded at ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 | --- | --- | |---------------------------------------------------------------------------------------------------------- ...

CUMBERLAND® PHARMACE UTICALS Corporate Presentation Nasdaq CPIX Safe Harbor Statement This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the d ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q1 2021 Earnings Conference Call May 11, 2021 4:30 PM ET Corporate Participants Erin Gull - Corporate Relations Manager A. J. Kazimi - Chairman and Chief Executive Officer Marty Cearnal - President and Chief Commercial Officer Michael Bonner - Chief Financial Officer Conference Call Participants Operator Thank you for joining Cumberland Pharmaceuticals First Quarter 2021 Financial Report and Company Update. This call is being recorded at the company's request a ...

_________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 of CUMBERLAND PHARMACEUTICALS INC. A Tennessee Corporation IRS Employer Identification No. 62-1765329 Commission file number 001-33637 2525 West End Avenue, Suite 950 Nashville, Tennessee 37203 (61 ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q4 2020 Earnings Conference Call March 9, 2021 4:30 PM ET Corporate Participants Erin Gull - Corporate Relations Manager A. J. Kazimi - Chairman and Chief Executive Officer Martin Cearnal - Executive Vice President and Chief Commercial Officer Michael Bonner - Senior Director Finance & Accounting, Chief Financial Officer Conference Call Participants Steve Kruger - Foresight Investment Operator Thank you for joining the Cumberland Pharmaceuticals Fourth Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 | --- | --- | |----------------------------------------------------------------------------------------|------------- ...

CUMBERLAND® PHARMACE UTICALS Corporate Presentation Nasdaq CPIX Safe Harbor Statement This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the d ...